title: [Erythema of rosacea: a new and effective treatment].
abstract: Until recently, our rosacea patients have had to suffer of their erythema with limited effective treatments. Mirvaso(®) (Brimonidine tartrate 0.5%, Brimonidine 3mg/g) is a new medication, indicated for the treatment of the erythema of rosacea. The phase III pivotal and long term studies showing the efficacy and tolerability of Mirvaso(®) are summarized.
authors.affiliation: 755 Mount Vernon Hwy Ne 430, Atlanta - GA 30328-4274, États-Unis. Electronic address: fghom@yahoo.com.
authors.forename: F G
authors.initials: FG
authors.lastname: Hougeir
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists / Q000627:therapeutic use*; D000068438:Brimonidine Tartrate; D004890:Erythema / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011810:Quinoxalines / Q000627:therapeutic use*; D012393:Rosacea / Q000150:complications*; D016896:Treatment Outcome
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D011810:Quinoxalines; D000068438:Brimonidine Tartrate
keywords: Brimonidine; Erythema; Rosacea; Rosacée; Érythème